Tag: angioplasty

Summa Therapeutics receive FDA approval for injectable angioplasty balloon catheter

Summa Therapeutics, a specialty angioplasty balloon medical device company, announced today that its innovative line of injectable angioplasty balloon catheters has been cleared for...
advance serenity

Advance Serenity PTA balloon now available in more sizes and locations

As announced at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM 2023; 14–17 June, National Harbor, USA), the Advance Serenity hydrophilic percutaneous...
RECOIL study

PRELUDE-BTK subanalysis highlights superior lumen gain, greater volumetric blood flow using...

Cagent Vascular has announced the results of a comparative subanalysis of the PRELUDE-below-the-knee (BTK) study versus plain balloon angioplasty. The study was led by Marianne...

Chocolate Touch drug-coated angioplasty balloon for treatment of PAD receives FDA...

Genesis MedTech Group announced that the US Food and Drug Administration (FDA) has approved the Chocolate Touch drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA)...

Transit Scientific announces US FDA clearance for XO RX angioplasty platform

Transit Scientific has announced that the XO RX 2.2Fr and XO RX 3.8Fr platform has received US Food and Drug Administration (FDA) clearance to...

Continued clinical success reported with cutting-edge vessel prep device

Transit Scientific had shared via press release successful outcomes on multiple fistula and graft cases using its XO Score sheath platform, a first-of-its-kind metal-alloy...
oversized balloon angioplasty

Oversized balloon angioplasty technique safe and effective for AV fistula maturation

A retrospective analysis published in the Journal of Vascular Access (JVA) has shown that the oversized balloon angioplasty technique to assist arteriovenous (AV) fistula...
magictouch scb

Concept Medical provides update on IMPRESSION trial to evaluate MagicTouch AVF

Concept Medical has provided an update on the progress of the IMPRESSION (Sirolimus-coated balloon angioplasty versus plain balloon angioplasty in the treatment of dialysis...

New tools for CLTI: ISET audience hear what’s on the horizon...

“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...
CLTI

New tools for CLTI: ISET audience hear what’s on the horizon...

“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider (University of California San Francisco, San Francisco,...

B Braun announces publication of 12-month LOCOMOTIVE EXTENDED results

B Braun has revealed that 12-month results from the LOCOMOTIVE EXTENDED study of the company’s Multi-Loc multiple stent delivery system have been published in...
covered

24-month AVeNEW study results: Covered stent angioplasty “statistically superior” to angioplasty...

Against the backdrop of increasing end-stage renal disease (ESRD) prevalence in the USA, Bart Dolmatch (Portola Valley, USA) presented the 24-month results of the...

Infinity angioplasty balloon catheter receives 510(k) clearance

The Infinity Angioplasty Balloon Company has announced that its balloon platform—the Infinity angioplasty balloon catheter—has been cleared by the US Food and Drug Administration...

Pedal artery revascularisation: Is it ready for prime time?

Reviewing the available evidence for below-the-ankle interventions in the treatment of critical limb-threatening ischaemia (CLTI), Srini Tummala proposes that pedal artery intervention “should be...

Real-world data with long-term follow-up confirm no increased mortality signal with...

Data from an unselected, real-world cohort of 64,000 claimants of the German BARMER Health Insurance reveals no signal of increased long-term mortality when paclitaxel-based...

Impressions from LINC 2020: Strong clinical and economic case for widespread...

NOTE: This video is ONLY available to watch in selected countries and geographies Andrew Holden (Auckland, New Zealand), Alexandros Mallios (Paris, France), Robert Lookstein (New...

Shockwave IVL can aid in eliminating recoil and dissection during below-the-knee...

George Adams (Raleigh, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about the benefits of using easy-to-use Shockwave IVL (Intravascular Lithotripsy) in calcified...

Lutonix BTK IDE: First Level 1 evidence of positive safety and...

 Patrick Geraghty (St Louis, USA) presented new datapoints from the six-month outcomes of the Lutonix BTK IDE trial at the 2018 VEITHsymposium (13–17 November,...

TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for...

Thomas Zeller (Bad Krozingen, Germany) delves into data and design of the TOBA II (Tack Optimized Balloon Angioplasty II) trial with principal investigator William...

LimFlow completes enrolment in US feasibility study

LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....

AV Medical’s Chameleon receives expanded indication to include infusion of diagnostic...

AV Medical Technologies has announced that its Chameleon PTA balloon catheter has received FDA clearance for an expanded indication to include infusion of diagnostic...

Positive late-breaking DANCE clinical trial data presented at VIVA 2016

Christopher Owens, associate professor of Surgery in the Division of Vascular and Endovascular Surgery at the University of California, San Francisco (UCSF), USA, has...

TOBA study results demonstrate 76.4% 12-month primary patency and 89.5% freedom...

The one-year results from Intact Vascular’s Tack Optimized Balloon Angioplasty (TOBA) clinical study have been published in the Journal of Vascular Surgery. The TOBA study...

AV Medical announces initial Chameleon PTA balloon catheter US experience

AV Medical has commenced cases in the USA with its Chameleon angioplasty balloon catheter. With its Supervision design, an AV Medical press release says...